mortality/aging
|
• sudden death occurring within 5 weeks of tamoxifen administration (at 6 weeks) is observed
• one mouse that developed spontaneous ventricular tachycardia died suddenly prior to any electrophysiological testing
|
|
• following tamoxifen treatment starting at 6 weeks, animals demonstrate sudden death as soon as 5 weeks post administration
|
cardiovascular system
| N |
• mutants have similar contractile function to controls; mice display immediate recovery of normal cardiac function after episodes of spontaneous ventricular tachycardia
|
|
• displayed by some tamoxifen-treated mutants; in ambulatory studies and electrophysiologic (EP) studies, spontaneous monomorphic ventricular tachycardia episodes are observed in some mice
• mice show significantly increased susceptibility to ventricular tachycardia after burst stimulation in EP studies
|
|
• significant arrhythmias are observed in tamoxifen-treated mutants, including Mobitz type II second-degree AV block (indicating infranodal conduction system disease)
|
|
• premature ventricular contractions (PVCs) numbering more than 100 per 24 hour period are detected in more than half of mutant mice
|
|
• severe conduction slowing is observed in tamoxifen-treated animals 4-5 weeks after tamoxifen administration; the PR interval and QRS duration are significantly increased compared to controls
|
|
• slowed conductance through the His bundle is detected; non-ventricular conduction system (VCS) function is not altered
|


Analysis Tools